Nambi P, Pullen M, Wu H L, Aiyar N, Ohlstein E H, Edwards R M
Department of Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406.
Endocrinology. 1992 Sep;131(3):1081-6. doi: 10.1210/endo.131.3.1324149.
High affinity and high density endothelin (ET)-binding sites were identified in membranes prepared from human kidney cortex and medulla. Saturation binding experiments performed in membranes prepared from cortex and medulla using [125I]ET-1 and [125I]ET-3 revealed that the proportion of [125I]ET-3-binding sites was 30-35% less than that of [125I]ET-1-binding sites. The apparent dissociation constants and maximum binding for [125I]ET-1 and [125I]ET-3 to membranes from cortex were 91 +/- 5 pM and 165 +/- 10 fmol/mg protein, and 117 +/- 9 pM and 110 +/- 7 fmol/mg protein, respectively, whereas in medulla they were 139 +/- 10 pM and 360 +/- 11 fmol/mg protein, and 142 +/- 11 pM and 245 +/- 15 fmol/mg protein, respectively. In the presence of 10 nM sarafotoxin-6c, which is selective for ETB receptors, [125I]ET-1 binding was decreased by 65-70%, whereas [125I]ET-3 binding was totally abolished, suggesting that 65-70% of [125I]ET-1 binding and 100% of [125I]ET-3 binding was to ETB receptors. This was further confirmed by the use of a cyclic pentapeptide [cyclo(D-Trp,D-Asp,L-Pro, D-Val,L-Leu)] (BQ123), which is selective for ETA receptors. In the presence of 1 microM BQ123, [125I]ET-1 binding was decreased by 25-30%, whereas [125I]ET-3 binding was unaffected, confirming that 30-35% of ET receptors belong to the ETA subtypes, and that [125I]ET-1 bound to both ETA and ETB receptors with the same high affinity, but [125I]ET-3 bound only to ETB receptors with high affinity. These results suggest that human kidney cortex and medulla contain ETA and ETB receptors in a ratio of 30:70, and that sarafotoxin-6c and BQ123 are valuable tools in identifying the subtype of ET receptors in various tissues.
在从人肾皮质和髓质制备的膜中鉴定出高亲和力和高密度的内皮素(ET)结合位点。使用[125I]ET-1和[125I]ET-3对皮质和髓质制备的膜进行的饱和结合实验表明,[125I]ET-3结合位点的比例比[125I]ET-1结合位点少30-35%。[125I]ET-1和[125I]ET-3与皮质膜的表观解离常数和最大结合量分别为91±5 pM和165±10 fmol/mg蛋白,以及117±9 pM和110±7 fmol/mg蛋白,而在髓质中分别为139±10 pM和360±11 fmol/mg蛋白,以及142±11 pM和245±15 fmol/mg蛋白。在对ETB受体具有选择性的10 nM 6c-肉瘤毒素存在下,[125I]ET-1结合减少了65-70%,而[125I]ET-3结合完全被消除,这表明65-70%的[125I]ET-1结合和100%的[125I]ET-3结合是与ETB受体结合。对ETA受体具有选择性的环五肽[环(D-色氨酸,D-天冬氨酸,L-脯氨酸,D-缬氨酸,L-亮氨酸)](BQ123)的使用进一步证实了这一点。在1 μM BQ123存在下,[125I]ET-1结合减少了25-30%,而[125I]ET-3结合未受影响,这证实了30-35%的ET受体属于ETA亚型,并且[125I]ET-1以相同的高亲和力与ETA和ETB受体结合,但[125I]ET-3仅以高亲和力与ETB受体结合。这些结果表明,人肾皮质和髓质中ETA和ETB受体的比例为30:70,并且6c-肉瘤毒素和BQ123是鉴定各种组织中ET受体亚型的有价值工具。